Retatrutide Dubai: UAE Price, Availability & Delivery

Retatrutide Research-Use Status and Product Context

Retatrutide (LY-3437943) is a triple-agonist peptide developed by Eli Lilly that simultaneously activates three metabolic receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and GCGR (glucagon receptor). This triple mechanism of action has earned it the informal label “GLP-3” in online research communities, though no actual hormone by that name exists. Our triple-agonist pathway analysis explains how these three receptors interact at the molecular level.

In a pivotal Phase 2 trial published in the New England Journal of Medicine (DOI: 10.1056/NEJMoa2301972), Retatrutide demonstrated a 24.2% mean body weight reduction at the highest dose over 48 weeks—surpassing the efficacy observed with single-agonist (semaglutide, ~15%) and dual-agonist (tirzepatide, ~22.5%) compounds in comparable timeframes.

Eli Lilly’s Phase 3 TRIUMPH clinical trial program is currently underway, with additional readouts still expected in 2026 and no publicly announced NDA filing date as of April 22, 2026. Retatrutide remains investigational and has not received FDA or UAE approval. This page is therefore limited to research-use sourcing context in Dubai; the full regulatory timeline lives on our retatrutide approval status page. For a UAE-specific check of current study listings, see our retatrutide clinical trials UAE review.

Retatrutide Weight Loss Data From Phase 2 and TRIUMPH

Retatrutide has demonstrated some of the most significant weight loss results of any investigational obesity medication to date. In early trials, patients receiving the highest dose achieved a mean 24.2% body weight reduction over 48 weeks—translating to substantial weight loss for individuals with obesity or overweight conditions. At this rate, retatrutide can achieve up to 24% body-weight reduction per treatment course, making it the most effective compound in clinical trials for metabolic weight loss research to date.

Phase 2 Weight Loss Outcomes

The Phase 2 dose-finding study enrolled patients with a BMI of 30 or above. Retatrutide produced dose-dependent weight loss across all treatment arms, with more significant changes observed at higher doses. Particularly those receiving 12 mg weekly can expect weight loss exceeding 20% of baseline body weight. These weight loss results surpassed the effectiveness of approved weight loss medications including semaglutide and tirzepatide in comparable trial durations. For context on how approved GLP-1 compounds perform in practice, see our Ozempic and Mounjaro before and after weight loss data.

What to Expect from Ongoing Trials

Phase 3 TRIUMPH trials (ClinicalTrials.gov) are evaluating retatrutide weight loss in larger, more diverse patient populations across multiple geographies. Researchers expect the data to confirm whether retatrutide leads to sustained weight loss over 72 weeks and whether the weight loss benefits extend to cardiovascular risk reduction, liver fat reduction, and metabolic syndrome outcomes. Dubai-based research institutions studying retatrutide weight loss mechanisms can access verified research-grade material through Remy Peptides.

How Retatrutide Affects Appetite, Metabolism, and Energy Expenditure

Retatrutide’s triple-agonist mechanism targets appetite regulation and metabolic control through multiple combined pathways. The GLP-1 component reduces appetite and hunger signals via hypothalamic satiety centres, while activation of glucagon receptors enhances energy expenditure and fat oxidation. The GIP component further supports glycemic regulation and influences adipose tissue insulin response. This triple-agonist approach represents an evolution in metabolic control compared to single and dual agonists.

Appetite Regulation & Hunger Suppression

GLP-1 receptor activation slows gastric emptying and enhances appetite suppression, reducing overall caloric intake. GIP receptor engagement further modulates appetite through central nervous system signalling. Together, these combined targets produce sustained hunger reduction and improved appetite control—contributing to the significant weight loss observed in clinical trials.

Fat Metabolism & Energy Expenditure

The glucagon receptor component specifically activates hepatic fat metabolism and metabolic processes that increase energy expenditure. This metabolic boost is what distinguishes retatrutide from single- and dual-agonist treatments, potentially leading to improved energy levels and more efficient lipid oxidation during weight loss.

Retatrutide Data for Blood Sugar and Insulin Sensitivity

Beyond weight loss, retatrutide research has revealed significant improvements in blood sugar control and metabolic health markers. GLP-1 and GIP receptor activation enhances insulin secretion in a glucose-dependent manner, improving blood sugar regulation without increasing hypoglycaemia risk.

Patients with type 2 diabetes in the Phase 2 study showed improved insulin sensitivity and reduced HbA1c levels alongside weight loss. This dual benefit is important for researchers investigating metabolic syndrome, where obesity and diabetes co-occur. Retatrutide’s ability to address both blood sugar dysregulation and excess body weight through a single combination therapy molecule makes it a focus of metabolic health research worldwide.

Why Dubai Researchers Use Prefilled Retatrutide Pens

Dubai’s extreme climate—with ambient temperatures regularly exceeding 45°C during summer months—makes cold-chain integrity critical for peptide research materials. Prefilled Pen formats offer distinct advantages over traditional lyophilised powder vials in this environment.

• Contamination risk: Prefilled pens eliminate the reconstitution step required with powder vials (see our reconstitution guide for the powder workflow), removing the primary contamination vector in laboratory handling
• Dosing accuracy: Click-based dosing (0.1mg per click on the 30mg pen) provides reproducible precision without manual volumetric measurement (see the full click chart for every dose)
• Temperature stability: Remy Peptides ships all pens in temperature-controlled packaging with cold-chain monitoring, ensuring material integrity from dispatch to laboratory receipt
• COA verification: Every batch is independently tested by Janoshik Analytical, with batch-specific Certificates of Analysis published and verifiable: 30mg pen RETP002 at 99.262%, 20mg pen RET-20-C-2604-001 at 99.841%, and vial line RET-20-V-2604-001 at 99.741%

For research facilities in Dubai and across the UAE, the prefilled pen format reduces handling variables and supports consistent experimental protocols—critical factors when working with high-value research compounds. Our retatrutide dosage and titration guide covers the click-based dosing protocols used in published trials.

Retatrutide Price in Dubai by Order Size

Remy Peptides offers tiered pricing for research institutions and laboratories conducting in-vitro studies with Retatrutide. Volume tiers reduce the per-pen cost for larger research programs, making multi-week protocols more accessible. All prices are in AED (United Arab Emirates Dirham) and include free UAE delivery.

• 1 pen: AED 1,800 (30mg) / AED 1,200 (20mg)
• 3-pack: AED 1,650/pen (30mg) / AED 1,050/pen (20mg) — save AED 450
• 5-pack: AED 1,500/pen (30mg) / AED 900/pen (20mg) — save AED 1,500

All orders include a Janoshik-verified Certificate of Analysis, temperature-controlled cold-chain delivery, and WhatsApp support for order tracking and delivery coordination. Payment is accepted via card (secure payment link), cash on delivery, or USDT (TRC-20).

For bulk research orders or institutional procurement beyond the standard tiers, enquiries can be submitted via Telegram at @RemyPeptides. Bulk pricing is available for multi-month research protocols and laboratory supply agreements.

Dubai Cost per Milligram

For laboratories running multi-week research protocols, the total cost per milligram is often more relevant than the per-pen price. Volume-tier pricing at Remy Peptides is designed to reduce the per-milligram cost for sustained research programs in the UAE.

Using the current 30mg pen tiers, the effective cost per milligram is:

• Single pen order: AED 1,800 for 30mg — AED 60/mg
• 3-pack order: AED 4,950 for 90mg — AED 55/mg
• 5-pack order: AED 7,500 for 150mg — AED 50/mg

For context, most research-grade retatrutide pens in the UAE market are priced between AED 1,400–1,800 per 30mg unit with limited volume incentives. The volume-tier structure at Remy Peptides is designed to support sustained research protocols—particularly the standard 24-week and 48-week titration schedules modelled on the TRIUMPH clinical trial design—without requiring repeated single-unit procurement at premium rates.

This pricing applies to all UAE orders, with same-day Dubai dispatch and the same temperature-controlled logistics regardless of order size.

Retatrutide vs Mounjaro, Wegovy, and Other GLP-1 Options

The key differentiator for Retatrutide is its triple-receptor mechanism. Approved GLP-1 therapies and next-generation compounds vary in the number of metabolic receptors they engage, which directly correlates with observed efficacy in clinical trials.

• Semaglutide (Ozempic in Dubai / Wegovy): Single receptor (GLP-1 only) — ~15% body weight reduction in trials
• Tirzepatide (Mounjaro in Dubai): Dual receptor (GLP-1 + GIP) — ~22.5% body weight reduction in trials
• Retatrutide: Triple receptor (GLP-1 + GIP + glucagon) — 24.2% body weight reduction in Phase 2 data

For a local overview of approved options, compare Ozempic in Dubai, Mounjaro in Dubai, and our weight loss injections in Dubai guide.

The addition of the glucagon receptor agonism is hypothesised to increase energy expenditure and hepatic lipid oxidation, potentially contributing to the incremental efficacy observed over dual-agonist compounds. Phase 3 data from the TRIUMPH program will provide definitive comparative results. Browse our best research peptides guide for a full overview of compounds available for laboratory study.

For a detailed breakdown including efficacy comparisons, dosing schedules, and mechanism analysis, see our full Retatrutide vs Tirzepatide vs CagriSema comparison.

Dubai and UAE Delivery Windows for Research Orders

Remy Peptides provides temperature-controlled delivery for all research peptide orders across the United Arab Emirates. Delivery timelines vary by emirate, with all shipments dispatched from our Dubai facility using insulated cold-chain packaging. For a complete overview of available compounds beyond retatrutide, see our research peptides in Dubai page.

• Dubai: Same-day delivery (order by 4 PM) — all areas including DIFC, Downtown, JBR, JLT, Business Bay, Dubai Marina, and Dubai Hills
• Abu Dhabi: Next-day delivery (order by 12 PM)
• Sharjah: Next-day delivery (order by 12 PM)
• Ajman: Next-day delivery (order by 12 PM)
• Other emirates: Next-day delivery (order by 12 PM) — Ras Al Khaimah, Umm Al Quwain, Fujairah

All shipments use insulated, temperature-controlled packaging to maintain cold-chain integrity from dispatch to laboratory receipt. This is especially critical during summer months when ambient temperatures in the UAE regularly exceed 45°C.

For order tracking, delivery coordination, or research enquiries, contact us via WhatsApp. Support is available 7 days a week, 10 AM to 10 PM UAE time. We also accept enquiries in Arabic via WhatsApp.

Lifestyle and Long-Term Interpretation of Retatrutide Data

Effective weight management extends beyond pharmacological treatments alone. Research into retatrutide and other weight loss medications increasingly focuses on combined approaches that integrate lifestyle changes, resistance training, and nutritional support alongside the compound itself. Exercise—particularly resistance training and structured protein intake—has been shown to preserve lean muscle mass during rapid weight loss and support long-term weight management outcomes. Nutritional coaching and metabolic monitoring are considered essential components of any comprehensive protocol involving GLP-1-class compounds.

Obesity Treatments & Public Health

The availability of next-generation obesity treatments like retatrutide has significant public health implications, particularly in the UAE where obesity prevalence exceeds 30%. Researchers are studying individual factors that influence treatment response, including genetics, baseline metabolic health, and lifestyle habits. Benefits may vary based on these individual factors, and combining retatrutide with exercise and lifestyle modifications may lead to more significant and sustained weight loss results.

Is Retatrutide Legal in the UAE?

Retatrutide is not a controlled substance in the UAE. As an investigational compound that has not yet received FDA or any other regulatory approval, it falls outside the scope of scheduled pharmaceutical regulations. In the UAE, research-grade peptides that are clearly labelled for in-vitro laboratory use and are not marketed for human consumption operate within the existing regulatory framework under MoHAP Circular 17/2022.

Remy Peptides supplies retatrutide exclusively for in-vitro research purposes. All materials carry “For Research Use Only” labelling, and no therapeutic claims are made. This is distinct from prescription GLP-1 medications like semaglutide (Ozempic/Wegovy) or tirzepatide (Mounjaro), which are regulated pharmaceuticals available only through licensed pharmacies with a prescription in the UAE.

For a broader overview of peptide legality across jurisdictions, see our peptide legality guide by country. For a Dubai-specific reading of the public-source compliance position, see our Dubai legality brief.

Retatrutide Availability in the UAE (2026)

As of April 22, 2026, retatrutide is not available through any UAE pharmacy, clinic, or hospital. Eli Lilly’s Phase 3 TRIUMPH clinical trials are ongoing globally, and Lilly has not announced an NDA filing date. Even after any future approval, UAE availability through clinical channels would require separate regulatory review by the UAE Ministry of Health and Prevention (MoHAP).

For researchers who require retatrutide for in-vitro laboratory studies, Remy Peptides is currently the only UAE-based supplier offering Janoshik-verified, HPLC-tested material with same-day Dubai delivery and full certificate of analysis documentation. The prefilled pen format eliminates the need for reconstitution, reducing contamination risk and handling time in laboratory settings.

Retatrutide Research Use and Sourcing in Dubai

Retatrutide availability in Dubai for research purposes is supported through Remy Peptides. As a pre-approval investigational drug, retatrutide is not yet available through pharmacies or clinical channels in the UAE. For a global overview of sourcing options and quality verification criteria, see our supplier checklist. Remy Peptides provides retatrutide in Dubai exclusively for in-vitro laboratory research, with all materials clearly labelled “For Research Use Only.”

Dubai-based researchers studying retatrutide can focus on mechanism validation, receptor binding assays, or metabolic pathway analysis using our HPLC-verified research-grade peptides. For a broader look at what is driving research demand in the region, see our peptide trends in the UAE for 2026. For a complete guide to peptide therapy options in Dubai—clinics, costs, and research-grade access—see our peptide therapy Dubai guide. For questions about retatrutide research use, availability, or bulk procurement in Dubai, contact our research support team via WhatsApp.